Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vinflunine + best supportive care
- Development stage
- Unknown
- Lead developer
- Pierre Fabre
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Vinflunine is a novel fluorinated vinca alkaloid and microtubule inhibitor developed by Pierre Fabre Médicament. It is specifically indicated as a second-line treatment for advanced or metastatic transitional cell carcinoma of the urothelial tract (TCCU) after failure of a prior platinum-containing regimen. Unlike earlier vinca alkaloids, vinflunine exhibits a unique mechanism of action characterized by weaker binding to tubulin, which translates to higher antitumour activity and a distinct safety profile. In clinical practice, it is often administered alongside best supportive care (BSC), a regimen validated in a landmark Phase III trial (NCT00315237) that demonstrated a significant overall survival benefit compared to BSC alone.
- Other names
- vinflunine ditartrate
02
Targets
CaM (Calmodulin)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on vinflunine + best supportive care.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vinflunine + best supportive care.